Objectives: To evaluate the clinical outcomes of patients with cardiac sarcoidosis (CS) undergoing cardiac resynchronization therapy (CRT) among a cohort of patients with CS and cardiac implantable electronic devices. Background: CS manifests with conduction abnormalities, ventricular arrhythmias (VA), and heart failure (HF). While CRT improves outcomes in select nonischemic cardiomyopathies, its specific role in CS-related cardiomyopathy remains unclear. Methods: This retrospective cohort study included patients from the Johns Hopkins Cardiac Sarcoidosis Program (2004–2024) with a clinical or histological CS diagnosis who underwent ICD or pacemaker implantation, with or without CRT. Outcomes assessed included HF hospitalizations, appropriate anti-tachycardia pacing (ATP) or ICD shocks, heart transplantation, all-cause mortality, and a composite of these measures. Results: Among 212 patients (40.1% female, mean age 52.8 ± 11.1 years), 85 received CRT (82 CRT-D, 3 CRT-P). CRT recipients had significantly lower baseline left ventricular ejection fraction (LVEF) than non-CRT patients (mean difference: 11%; P < .01) but demonstrated greater LVEF improvement over time (1.43%; P = .03). During a follow-up of 6.15 ± 4.43 years, HF hospitalizations occurred in 12.7%, ATP/ICD shocks in 40.6%, and death in 8.0%. Composite outcomes occurred in 48.5% with no significant differences between CRT and non-CRT groups ( P = .50). CRT patients had lower freedom from HF hospitalizations ( P = .01) but similar arrhythmia treatment rates ( P = .70). Conclusions: CRT in CS was associated with improved LVEF but higher HF hospitalization rates and comparable VA treatment outcomes. These findings highlight the need for further research to optimize CRT utilization in this population.